keyboard_arrow_up

Inhalation & Nasal Spray Generic Drugs 2013 Research Report

ReportsnReports.com adds report Inhalation & Nasal Spray Generic Drugs 2013 to its store.  Around three quarters of the US$36.4 billion respiratory prescription drugs market comprises drugs that are delivered using inhalation or nasal spray technologies. The top five drugs used in the treatment of asthma and chronic obstructive pulmonary disease (COPD) attracted combined revenues of around US$18.0 billion in 2012. All five are blockbuster drugs. In terms of revenue, the current market leaders are GlaxoSmithKline’s Seretide/Advair (fluticasone propionate+salmeterol xianfoate), Boehringer Ingelheim’s Spiriva (tiotropium bromide) and AstraZeneca’s Symbicort (budesonide+formoterol). In the allergy segment, the leading nasal spray therapy used in the treatment of allergic rhinitis is Merck & Co’s Nasonex (mometasone furoate).

Complete report is available at http://www.reportsnreports.com/reports/231548-inhalation-nasal-spray-generic-drugs-2012.html.

High revenue originator drugs undoubtedly attract interest from prospective generic competitors. Unlike the oral generics market, however, where numerous companies typically compete for a revenue share, relatively few companies have the technology and expertise to compete in the market for generic inhalation and nasal spray products.

This report features the latest in-depth reviews of the market leaders, new products and competition across the wider respiratory drugs market and within the Asthma/ COPD and Allergic Rhinitis sectors. While also detailing information on the patents and generic company activity for products such as Seretide/Advair, Flixotide/Flovent, Ventolin and Combivent for Asthma/COPD and Nasonex, Rhinocort and Omnaris for Allergic Rhinitis... plus many more!

Order a copy of this report at http://www.reportsnreports.com/purchase.aspx?name=231548.

What this report contains:

  • Executive Summary
  • Comprehensive overview of the challenges and opportunities across the respiratory drugs market, and the FDA’s new product guidance forgeneric inhalers
  • Asthma/COPD sector breakdown with market overview, market leaders, new products and competition
  • Detailed look at the leading asthma/COPD products and their approvals, patents and market outlook
  • Allergic rhinitis sector breakdown with market overview, market leaders, new products and competition
  • Detailed look at the leading allergic rhinitis products and their approvals, patents and market outlook
  • Over 70 exportable tables and charts detailing patents, sales and FDA approvals (where available)

The Inhalation and Nasal Spray Generics report is the foolproof business resource for any industry executive who needs to fully understand the current products and future prospects for generics in the respiratory drugs market. The need for hard facts and statistics to back up everyday business decisions is essential and it is this report that can provide you with the answers.

Inquiry before Buying on this Report Inhalation & Nasal Spray Generic Drugs 2013 at http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=231548 before making a purchase decision.

About Us:
ReportsnReports.com is an online market research reports library of 350,000+ in-depth studies of over 5000 micro markets. Call +1 888 391 5441 with your research requirements or email the details on sales@reportsandreports.com  and we would be happy to help you find the business intelligence that you need. Not limited to the Pharmaceuticals ReportsnReports.com offers research studies on agriculture, consumer goods, , environment, advanced materials, public sector, food and beverages, energy and power, healthcare, automotive, manufacturing & construction, semiconductor and electronics, IT & telecommunication, pharmaceuticals, medical devices , retail, water, banking and financial services , advanced materials and much more.